Asset Details
Do you wish to reserve the book?
Metformin doses to ensure efficacy and safety in patients with reduced kidney function
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Metformin doses to ensure efficacy and safety in patients with reduced kidney function
Do you wish to request the book?
Metformin doses to ensure efficacy and safety in patients with reduced kidney function
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Metformin doses to ensure efficacy and safety in patients with reduced kidney function
2021
Overview
We aimed to develop a metformin dosing strategy to optimise efficacy and safety in patients with reduced kidney function. Metformin data from two studies stratified by kidney function were analysed. The relationship between metformin clearance and kidney function estimates was explored using a regression analysis. The maintenance dose range was predicted at different bands of kidney function to achieve an efficacy target of 1 mg/L for steady-state plasma concentrations. The dosing strategy was evaluated using simulations from a published metformin pharmacokinetic model to determine the probability of concentrations exceeding those associated with lactic acidosis risk, i.e. a steady-state average concentration of 3 mg/L and a maximum (peak) concentration of 5 mg/L. A strong relationship between metformin clearance and estimated kidney function using the Cockcroft and Gault (r 2 = 0.699), MDRD (r 2 = 0.717) and CKD-Epi (r 2 = 0.735) equations was found. The probability of exceeding the safety targets for plasma metformin concentration was <5% for most doses and kidney function levels. The lower dose of 500 mg daily was required to maintain concentrations below the safety limits for patients with an eGFR of 15–29 mL/min. Our analysis suggests that a maximum daily dose of 2250, 1700, 1250, 1000, and 500 in patients with normal kidney function, CKD stage 2, 3a, 3b and 4, respectively, will provide a reasonable probability of achieving efficacy and safety. Our results support the cautious of use metformin at appropriate doses in patients with impaired kidney function.
Publisher
Public Library of Science,Public Library of Science (PLoS)
Subject
/ Adult
/ Aged
/ Diabetes
/ Diabetes Mellitus, Type 2 - complications
/ Diabetes Mellitus, Type 2 - drug therapy
/ Dosage
/ Epidermal growth factor receptors
/ Female
/ Humans
/ Hypoglycemic Agents - administration & dosage
/ Hypoglycemic Agents - adverse effects
/ Hypoglycemic Agents - pharmacokinetics
/ Hypoglycemic Agents - therapeutic use
/ Kidney Diseases - complications
/ Kidneys
/ Male
/ Medicine
/ Medicine and Health Sciences
/ Metformin - administration & dosage
/ Metformin - pharmacokinetics
/ Patients
/ Pharmacy
/ Plasma
/ Practice guidelines (Medicine)
